Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clebopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.83 |
| ▸ | HTR4 known ✓ | Q13639 | 6/20 | 0.64 |
| ▸ | DRD4 | P21917 | 8/20 | 0.83 |
| ▸ | DRD3 | P35462 | 6/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.83 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.83 |
| ▸ | ACHE | P22303 | 1/20 | 0.83 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.83 |
| ▸ | HTR2A | P28223 | 1/20 | 0.83 |
| ▸ | HTR2C | P28335 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | HTR2B | P41595 | 1/20 | 0.83 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.83 |
| ▸ | HTR3A | P46098 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clebopride SCHEMBL25710 | 0.91 | DRD4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL25259199 | 0.91 | DRD4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL9867307 | 0.90 | DRD4 (0.98) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL11533888 | 0.88 | DRD4 (0.92) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL2323725 | 0.87 | CYP3A4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL4537448 | 0.87 | CYP3A4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| Clebopride SCHEMBL2323732 | 0.87 | CYP3A4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL11472928 | 0.86 | DRD4 (1.00) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL14454215 | 0.81 | DRD4 (0.80) | DRD4DRD2DRD3CYP3A4CYP1A2 | |
| SCHEMBL6840623 | 0.81 | HTR4 (0.80) | DRD4DRD2DRD3CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3918056-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | Stemonix Inc. (US) | 2021-12-08 | — | — | EP | claimed |
| US-20200400651-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | AXOSIM, INC. | 2020-12-24 | — | — | US | claimed |
| WO-2020160470-A1 | METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY | StemoniX Inc. (US) | 2020-08-06 | — | — | WO | claimed |
| CN-105878263-B | Pharmaceutical composition containing Amicos (Banyu) and its application | 高雯聪 | 2018-11-06 | — | — | CN | claimed |
| CN-106890264-A | A kind of pharmaceutical composition for preventing and treating gastric ulcer and its application | 张美荣 | 2017-06-27 | — | — | CN | claimed |
| CN-105878263-A | Medicine composition containing malic acid clebopride malate and application thereof | 杨强 | 2016-08-24 | — | — | CN | claimed |
| US-7223418-B2 | Stretchable patch | TIEJIN LIMITED (JP) | 2007-05-29 | — | — | US | claimed |
| CN-1504185-A | Pharmaceutical composition | 中外制药株式会社 | 2004-06-16 | — | — | CN | claimed |
| US-20020146445-A1 | Stretchable patch | TEIJIN LIMITED (JP) | 2002-10-10 | — | — | US | claimed |
| EP-1177786-A1 | STRETCHABLE PATCH | TEIJIN LIMITED (JP) | 2002-02-06 | — | — | EP | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-12638439-B2 | Method of using human spheroids for drug discovery | AXOSIM, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | GEXVAL INC. (JP) | 2026-01-01 | — | — | US | disclosed |
| EP-4548934-A1 | PHARMACEUTICAL COMPOSITION | Gexval Inc. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12036241-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-0752457-A2 | Hydrophilic adhesive base material | Kowa Company Ltd. (JP) | 1997-01-08 | — | — | EP | disclosed |
| EP-0735122-A2 | Adhesive base material | KOWA CO. LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0665009-A1 | CRYSTALLINE CONDITION DISLOCATING METHOD | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-08-02 | — | — | EP | disclosed |
| US-4978531-A | ANTIEMETICS | FORDONAL, S.A. (ES) | 1990-12-18 | — | — | US | disclosed |
| EP-0303445-A1 | Clebopride transdermal patch | WALTON S.A. (ES) | 1989-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000674-A1 | PHARMACEUTICAL COMPOSITION | HTR4, IL4, FFAR4 | DRD2 430/4885HTR4 1/4885DRD4 115/4885 |
| US-12638439-B2 | Method of using human spheroids for drug discovery | CACNA1E, PDE1B, ORAI1 | DRD2 554/4885HTR4 1441/4885DRD4 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.